Zacks: Analysts Expect Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Will Announce Quarterly Sales of $28.78 Million

Equities research analysts predict that Sangamo Therapeutics, Inc. (NASDAQ:SGMOGet Rating) will announce sales of $28.78 million for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Sangamo Therapeutics’ earnings, with estimates ranging from $17.00 million to $50.00 million. Sangamo Therapeutics reported sales of $26.28 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 9.5%. The company is scheduled to report its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Sangamo Therapeutics will report full-year sales of $114.55 million for the current fiscal year, with estimates ranging from $69.00 million to $212.00 million. For the next financial year, analysts expect that the company will post sales of $119.84 million, with estimates ranging from $30.00 million to $250.50 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover Sangamo Therapeutics.

Sangamo Therapeutics (NASDAQ:SGMOGet Rating) last announced its quarterly earnings results on Thursday, February 24th. The biopharmaceutical company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.08. The firm had revenue of $27.99 million during the quarter, compared to analysts’ expectations of $27.36 million. Sangamo Therapeutics had a negative net margin of 161.05% and a negative return on equity of 42.04%. The company’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same quarter last year, the company earned ($0.29) earnings per share.

A number of research analysts have recently issued reports on SGMO shares. StockNews.com began coverage on shares of Sangamo Therapeutics in a research note on Thursday, March 31st. They issued a “hold” rating for the company. Stifel Nicolaus lowered their price target on shares of Sangamo Therapeutics from $9.00 to $6.00 and set a “hold” rating for the company in a report on Thursday, January 6th. Truist Financial lowered their price target on shares of Sangamo Therapeutics from $23.00 to $19.00 and set a “buy” rating for the company in a report on Tuesday, April 5th. Wedbush reissued a “hold” rating and issued a $10.00 price target on shares of Sangamo Therapeutics in a report on Sunday, February 27th. Finally, Zacks Investment Research lowered shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, January 13th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, Sangamo Therapeutics presently has a consensus rating of “Hold” and an average price target of $14.92.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Alexandria Capital LLC lifted its position in Sangamo Therapeutics by 0.5% in the 3rd quarter. Alexandria Capital LLC now owns 960,470 shares of the biopharmaceutical company’s stock valued at $8,654,000 after acquiring an additional 4,943 shares in the last quarter. Strs Ohio lifted its position in Sangamo Therapeutics by 41.7% in the 3rd quarter. Strs Ohio now owns 57,800 shares of the biopharmaceutical company’s stock valued at $520,000 after acquiring an additional 17,000 shares in the last quarter. SG Americas Securities LLC lifted its position in Sangamo Therapeutics by 7.8% in the 3rd quarter. SG Americas Securities LLC now owns 667,781 shares of the biopharmaceutical company’s stock valued at $6,017,000 after acquiring an additional 48,356 shares in the last quarter. Lombard Odier Asset Management Switzerland SA lifted its position in Sangamo Therapeutics by 16.8% in the 3rd quarter. Lombard Odier Asset Management Switzerland SA now owns 1,409,736 shares of the biopharmaceutical company’s stock valued at $12,702,000 after acquiring an additional 202,795 shares in the last quarter. Finally, Natixis bought a new stake in Sangamo Therapeutics during the 3rd quarter worth about $217,000. 51.53% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ:SGMO traded down $0.25 during trading on Friday, reaching $5.44. The stock had a trading volume of 29,838 shares, compared to its average volume of 1,328,277. Sangamo Therapeutics has a 52 week low of $5.10 and a 52 week high of $12.83. The business’s 50-day moving average price is $5.80 and its 200 day moving average price is $7.37.

Sangamo Therapeutics Company Profile (Get Rating)

Sangamo Therapeutics, Inc, a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression.

Recommended Stories

Get a free copy of the Zacks research report on Sangamo Therapeutics (SGMO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.